Corcept Therapeutics Incorporated · NASDAQ:CORT
Corcept Therapeutics — SGO Annual Meeting on Women's Cancer 2026
18 slides from Corcept Therapeutics's conference presentation, Apr 10, 2026
Slide 1: SGO Annual Meeting, San Juan, PR, April 10-13, 2026
SAN JUAN, PR | APRIL 10-13, 2026 | WWW.SGO.ORG
Slide 2: Financial Disclosure
Financial Disclosure for: SAN JUAN, PR APRIL 10-13, 2026 Dr. Alexander B. Olawaiye I have the following financial relationships with ACCME defined ineligible companies to report over the past 24 months: AstraZeneca, Foundation Medicine, GSK, Merck, Daiichi Sankyo, Eisai, Corcept, and Eli Lilly Prese
Slide 3: Unlabeled/Investigational Uses
Unlabeled/Investigational Uses SAN JUAN, PR APRIL 10-13, 2026 Relacorilant in combination with nab-paclitaxel is FDA-approved as a treatment option for patients with platinum-resistant ovarian cancer, who have received 1–3 prior lines of therapy, including bevacizumab. This presentation may include
Slide 4: Final Overall Survival Results From the Phase 3 ROSELLA Trial
Final Overall Survival Results From the Phase 3 SAN JUAN, PR ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel APRIL 10-13, 2026 vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023) Alexander B Olawaiye,1
Slide 5: Background: Relacorilant Mechanism of Action
Relacorilant Mechanism of Action Background Relacorilant MOA Relacorilant Cortisol SAN JUAN, PR APRIL 10-13, 2026 • Patients with platinum-resistant ovarian cancer have an overall survival of ~1 year and need new Multiprotein Glucocorticoid treatments1 Complex Receptor • Ovarian cancers express the
Slide 6: Relacorilant Oncology Development Timeline
Relacorilant Oncology Development Timeline SAN JUAN, PR APRIL 10-13, 2026 Nab-paclitaxel is one of the most efficacious therapies in patients with platinum-resistant ovarian cancer;1-3 as it does not require steroid pretreatment, it is a rational partner for relacorilant May 2020 Mar 2021 Feb 2025 J
Slide 7: ROSELLA Study Schema
ROSELLA | Study Schema SAN JUAN, PR APRIL 10-13, 2026 * Relacorilant (150 mg PO) Nab-paclitaxel (80 mg/m2 IV) Population DAY 1 8 15 28 Dual Primary Endpoints ▪ Epithelial ovarian, primary ▪ Progression-free survival (PFS) by peritoneal, or fallopian tube RECIST v1.1 per blinded cancer N=381 Relacori
Slide 8: Baseline Characteristics Were Well Balanced
ROSELLA | Baseline Characteristics Were Well Balanced Relacorilant + Nab-paclitaxel (N=188) Nab-paclitaxel (N=193) Age, median (range), years 61 (26–85) 62 (33–86) SAN JUAN, PR APRIL 10-13, 2026 White 136 (72.3) 135 (69.9) Black or African-American 3 (1.6) 2 (1.0) Race, n (%) Asian (92% Korean) 22 (
Slide 9: Relacorilant Significantly Improved Progression-Free Survival
ROSELLA | Relacorilant Significantly Improved Progression-Free Survival Assessed by Blinded Review at the Primary Analysis SAN JUAN, PR APRIL 10-13, 2026 Relacorilant + Nab-paclitaxel Nab-paclitaxel N=193 N=188 Events, n (%) 113 (60.1) 121 (62.7) 6m PFS Median PFS, m 6.5 (5.6–7.4) 5.5 (3.9–5.9) (95%
Slide 10: Relacorilant Significantly Improved Overall Survival at Final Analysis
ROSELLA | Relacorilant Significantly Improved Overall Survival at the Final Analysis SAN JUAN, PR Relacorilant + APRIL 10-13, 2026 Nab-paclitaxel Nab-paclitaxel N=193 N=188 Events, n (%) 129 (69%) 159 (82%) Median OS, m 16.0 (13.0–18.3) 11.9 (10.0–13.8) (95% CI) HR (95% CI) 0.65 (0.51–0.83) P-value
Slide 11: Relacorilant Improved Overall Survival Across Key Subgroups
ROSELLA | Relacorilant Improved Overall Survival Across Key Subgroups Subgroup Patients, n Events, n Hazard Ratio (95% CI) All Patients 381 288 0.65 (0.51–0.83) SAN JUAN, PR APRIL 10-13, 2026 <65 years 229 172 0.75 (0.55–1.01) Age ≥65 years 152 116 0.58 (0.39–0.85) North America 90 71 0.47 (0.28–0.7
Slide 12: First and All Subsequent Therapies Were Well Balanced
ROSELLA | First and All Subsequent Therapies Were Well Balanced First Subsequent Anticancer Therapies* SAN JUAN, PR APRIL 10-13, 2026 100% 2 1 0 1 1 1 All Subsequent Systemic Anticancer Therapies 90% 1 11 1 10 2 1 Relacorilant + Nab-paclitaxel 80% Nab-paclitaxel Monotherapy Percentage of Participant
Slide 13: Safety Summary
ROSELLA | Safety Summary Relacorilant + Nab-paclitaxel was Well-Tolerated, with a Favorable and Consistent Safety Profile SAN JUAN, PR APRIL 10-13, 2026 Safety Population Who Received at Least Relacorilant + Nab-paclitaxel Nab-paclitaxel One Dose of Study Drug (N=378) (N=188) (N=190) Weeks of nab-pa
Slide 14: Treatment Discontinuations Due to Adverse Events Were Infrequent
ROSELLA | Treatment Discontinuations Due to Adverse Events Were Infrequent SAN JUAN, PR APRIL 10-13, 2026 Kaplan-Meier Curve Showing Time to First Onset of Adverse Events Leading to Treatment Discontinuation Relacorilant + Nab-paclitaxel Nab-paclitaxel N=190 N=188 Events, n (%) 18 (9.6%) 15 (7.9%) H
Slide 15: Common (>20%) Adverse Events
ROSELLA | Common (>20%) Adverse Events SAN JUAN, PR APRIL 10-13, 2026 When adjusted for duration of exposure, the incidence rates of neutropenia and anemia were similar between study arms. Peripheral neuropathy occurred with similar frequency in both arms (19.1% and 17.4%). 5 SAEs of febrile neutrop
Slide 16: Conclusions
ROSELLA | Conclusions SAN JUAN, PR APRIL 10-13, 2026 At the primary analysis, the addition of relacorilant (a first-in-class SGRA) to nab-paclitaxel resulted ROSELLA met both in a statistically and clinically significant improvement in PFS by BICR (HR 0.70, P=0.0076). dual primary 1 At the final ana
Slide 17: Acknowledgements
ROSELLA | Acknowledgements Thank you to all the patients, caregivers, family members, investigators, and site staff who supported this global trial. SAN JUAN, PR APRIL 10-13, 2026 Alvarez Jewell Barlow Cho Churruca Galaz Aguil Guerrero Agyemang-Prempeh Bellier Azzouquoa Knowles Clamp Kim de la Cueva
Slide 18: Access Full Manuscript
Access Full manuscript Copies of this presentation obtained through QR code are for personal use only and may not be reproduced without written permission of the authors. Scan to access Presentation
Corcept Therapeutics — SGO Annual Meeting on Women's Cancer 2026 on 6ix